ANPEP as a potential mediator linking aspartame exposure to MAFLD: insights from network toxicology and multi-omics

Long Xu1, Chi Zhang1, Shengliang Xin1

  • 1Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China.

Abstract

Insights

Aspartame (APM) exposure may increase the risk of metabolic-associated fatty liver disease (MAFLD) by upregulating ANPEP, a protein linked to liver inflammation and fibrosis. This suggests APM is not a safe weight management strategy.

Area of Science:

  • Biochemistry
  • Toxicology
  • Genomics

Background:

  • Aspartame (APM) is a common artificial sweetener linked to metabolic disorders.
  • Molecular mechanisms connecting APM to metabolic-associated fatty liver disease (MAFLD) are not well understood.

Purpose of the Study:

  • To investigate the molecular targets linking aspartame exposure to MAFLD.
  • To elucidate the role of these targets in the pathogenesis of MAFLD.

Main Methods:

  • Integrated network toxicology, molecular docking, molecular dynamics, machine learning, and transcriptomics.
  • Mendelian randomization and histological validation were employed.
  • Bulk and single-cell RNA sequencing were used to analyze gene expression.

Main Results:

  • Aspartame (APM) showed significant hepatotoxic potential.
  • ANPEP was identified as a key molecular target, showing strong binding with APM and upregulation in MAFLD liver tissues and mouse models.
  • Elevated ANPEP levels were significantly associated with increased MAFLD risk and were localized in myeloid cells during early fibrotic stages.

Conclusions:

  • ANPEP is a potential mediator linking aspartame exposure to MAFLD, inflammation, lipid dysregulation, and fibrosis.
  • Aspartame may pose risks for liver injury and MAFLD progression, questioning its safety for weight management.